Related Experiment Video
Updated: Apr 16, 2026

Induction of Ocular Surface Inflammation and Collection of Involved Tissues
Published on: August 4, 2022
Increased interleukin 23 (IL23) levels in schizophrenia patients treated with depot antipsychotic medication
Kara E O'Connell1, Jogin Thakore2, Kumlesh K Dev3
1Drug Development, School of Medicine, Trinity College Dublin, Ireland; Institute of Psychiatry, King's College London and The Maudsley Hospital, London, UK; St. Vincent's Hospital Fairview, Fairview, Dublin, Ireland.
Background:
Schizophrenia is a mental disorder, where genetic and environmental factors contribute to disease onset and progression. The immune system appears to play a role in schizophrenia, where altered cytokines levels and autoantibodies have been described. Notably however, to our knowledge, IL23 levels have not before been measured in schizophrenia patients treated with depot medication.
Methods:
We examined IL23 levels in serum samples obtained from patients with schizophrenia, treated with depot medication (n=35) compared with healthy controls (n=38) and correlated these levels with treatment time, patient age and illness severity.
Results:
IL23 levels were raised in depot treated groups compared with healthy controls. No correlation was observed, however, between IL23 levels and treatment time, patient age or illness severity.
Conclusions:
IL23 levels are raised in schizophrenia patients prescribed with depot medication, supporting the role of aberrant cytokine signalling in schizophrenia.
Related Concept Videos
Psychosis and Antipsychotic Drugs: Overview
Psychosis: Goals of Pharmacotherapy
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drug Therapy
Antianxiety Medications
Psychological and Sociocultural Causes of Schizophrenia
Antipsychotic Drugs: Typical and Atypical Agents

